Anti-VEGF Immunology Licensing Deal Terms at Phase 2: 2025 Benchmarks

The median upfront payment for an anti-VEGF immunology licensing deal at Phase 2 is now $120M. Total deal values in this segment range from $700M to $2.5B. And royalty rates have compressed into a surprisingly narrow 11%–18% band. Those numbers tell a story about where Big Pharma conviction sits right now — and it's not where most biotech founders think. If you're negotiating anti-VEGF immunology licensing deal terms at Phase 2, the 2025 landscape demands a recalibration of assumptions. The era of splashy headline numbers masking thin upfront commitments is fully here, and understanding the structural mechanics behind these deals is the difference between a good outcome and a great one.

This article lays out the verified benchmark data, deconstructs the most relevant comparable transactions, introduces a framework for evaluating deal quality beyond total value, and provides a concrete negotiation playbook. If you're a biotech founder preparing for a partnering discussion or a BD professional building a deal committee deck, this is the reference document you need.

The Phase 2 Anti-VEGF Immunology Licensing Market Right Now

Anti-VEGF therapeutics in immunology occupy an unusual position in the 2025 deal landscape. The modality is mature — Avastin, Eylea, and Lucentis proved the commercial thesis decades ago — but new entrants are targeting differentiated immunology indications, novel formulations, and next-generation constructs that promise improved efficacy, durability, or safety. Buyers are interested, but they're pricing risk with surgical precision.

Phase 2 is the inflection point. Pre-Phase 2, you're selling a hypothesis. Post-Phase 2, you're selling a de-risked asset with a price tag that reflects it. At Phase 2, you're selling conviction — and the deal structures reflect exactly how much (or how little) the buyer has.

Here's where the benchmark data lands for anti-VEGF immunology licensing deal terms at Phase 2:

Several things jump out immediately. The upfront-to-total-value ratio is wide — ranging from 4% to 36%. That variance is not noise. It's signal. It tells you that some buyers are placing small option bets with enormous back-end structures they may never pay, while others are writing large checks because the data compels them. We'll unpack what separates these archetypes below.

For a deeper dive into immunology-specific benchmarks across all modalities, see our Immunology Deal Benchmarks page, which tracks upfront, milestone, and royalty trends by phase and modality.

What the data actually says: The median upfront of $120M signals genuine buyer interest, but the spread between $60M and $250M is enormous for a single modality-phase-TA combination. The primary driver of that variance is data maturity within Phase 2 — early Phase 2a data commands the low end; late Phase 2b with a clear registrational path commands the high end.

What the Benchmark Data Reveals

Let's move past the summary statistics and into what the data actually means for deal strategy.

Upfront Payments: The Real Currency of Conviction

An upfront payment is the only non-contingent cash in a licensing deal. Everything else — milestones, royalties, commercial targets — is a promise. When a buyer writes a $250M upfront check for a Phase 2 anti-VEGF immunology asset, they're telling you three things: the data is differentiated, the indication is commercially validated, and their internal pipeline has a gap they need to fill on a specific timeline.

When they write a $60M check with $640M in milestones to reach the low end of total value, they're telling you something very different: they like the science, but they want you to bear the clinical risk. That's not conviction. That's an option.

Royalty Rates: The Forgotten Lever

The 11%–18% royalty band for Phase 2 anti-VEGF immunology licensing deals is narrower than most founders expect. And within that band, the real negotiation isn't the headline rate — it's the tier structure. A flat 14% royalty on all net sales is worth dramatically more than an 18% rate that only kicks in above $2B in cumulative sales, with 11% on the first tier. Yet most term sheets are structured with escalating tiers, and most founders celebrate the top-tier number without modeling the probability-weighted revenue at each tier.

What the data actually says: Royalty rates in this segment have compressed. The difference between a good deal and a great deal is not 11% vs. 18% — it's how the tiers are structured, what the base rate covers, and whether there are step-downs for biosimilar entry or co-promotion offsets.

Total Deal Value: The Most Misleading Number in Biopharma

Total deal value is the number that makes press releases. It's also the number most likely to mislead. A $2.5B total deal value with a $60M upfront and $2.44B in milestones tied to Phase 3 completion, regulatory approval in three geographies, and commercial sales thresholds above $1B annually is — in expected value terms — worth a fraction of its headline. The probability-weighted value of that deal might be $300M–$500M. A $700M deal with a $250M upfront and achievable near-term milestones might actually deliver more cash.

This is why we built the Deal Calculator — to help both sides model probability-adjusted deal value rather than relying on headline figures.

Deal Deconstruction: How the Biggest Immunology Licensing Deals Were Structured

Now let's examine the 2025 comparable deals that are shaping expectations for anti-VEGF immunology licensing deal terms at Phase 2. Not all of these are anti-VEGF specifically, but they represent the immunology licensing market that buyers and sellers are benchmarking against.

Blueprint Medicines → Sanofi: The Ceiling

This is a $9.5B acquisition, not a licensing deal. But it matters because it reset expectations for what immunology assets are worth. Sanofi paid full price — 100% upfront, no milestone tail — because Blueprint's portfolio was de-risked, differentiated, and addressed indications Sanofi needed to fill. For anyone negotiating a Phase 2 licensing deal, this transaction established the upper bound of what a buyer will pay when they have maximum conviction and minimum alternatives.

The lesson: if your Phase 2 data is strong enough and you're willing to sell the whole company, the premium is significant. If you're licensing, you're voluntarily taking a discount to that ceiling in exchange for retained economics and optionality. Make sure the discount is worth it.

Nimbus Therapeutics → Takeda: What 67% Upfront Looks Like

The Nimbus-Takeda deal is the most structurally instructive transaction of 2025 for immunology licensing. A $4B upfront on a $6B total is a 67% upfront ratio. That's almost unheard of in licensing. It tells you Takeda's deal team went to their board with data compelling enough to justify committing two-thirds of the total economics at signing.

What drove that structure? Three factors. First, Nimbus's TYK2 inhibitor had differentiated Phase 2 data in a competitive landscape where best-in-class positioning was clear. Second, Takeda's immunology pipeline had a well-documented gap. Third, the competitive tension in the process — multiple potential buyers — gave Nimbus leverage to demand front-loaded economics.

For a biotech founder with Phase 2 anti-VEGF data, this deal proves that upfront ratios above 50% are achievable, but only when the data is unambiguous and the process is competitive.

The Zero-Upfront Trio: RemeGen, Earendil, and Capstan

Three of the five largest immunology-adjacent deals in 2025 had zero upfront payments. Read that again. RemeGen-Vor Bio ($4B total, $0 upfront). Earendil Labs-Sanofi ($2.56B total, $0 upfront). Capstan Therapeutics-AbbVie ($2.1B total, $0 upfront).

These deals are structurally very different from the Nimbus and Blueprint transactions. They are options. The buyer is saying: "We believe in the potential, but we're not willing to commit capital until clinical milestones de-risk the investment." For the licensor, this means you're funding your own development with the promise of future payments that may or may not materialize.

The critical question for any founder looking at a zero-upfront term sheet: do you have the runway to reach the first meaningful milestone without the upfront cash? If the answer is no, the deal is effectively a down round disguised as a partnership. If the answer is yes, and the milestone payments are large and achievable, it can be a rational structure — especially if the total deal value is genuinely large and the royalty rates are at the top of the range.

What the data actually says: Zero-upfront deals are not inherently bad, but they shift all near-term risk to the licensor. In the anti-VEGF immunology Phase 2 segment, where the median upfront is $120M, accepting $0 requires either exceptional total economics or a balance sheet that can absorb 18–24 months of additional development cost without dilution.

The Framework: The Conviction Ratio

We introduce a framework we call "The Conviction Ratio" — a simple but powerful metric for evaluating the quality of a licensing deal beyond its headline numbers.

Conviction Ratio = Upfront Payment ÷ Total Deal Value

This ratio tells you what percentage of the total economics the buyer is willing to commit non-contingently at signing. It is the single best proxy for buyer conviction, and it should be the first number every biotech founder and BD professional calculates when evaluating a term sheet.

Here's how to interpret it:

• Conviction Ratio > 50%: The buyer is all-in. They believe the asset will succeed, and they're paying for that belief. This is Nimbus-Takeda territory. Expect this only with differentiated late-Phase 2 data in validated indications with competitive process dynamics.
• Conviction Ratio 15%–50%: The buyer has strong interest but is managing downside risk through milestone gating. This is the healthy range for most Phase 2 anti-VEGF immunology licensing deals. The median in our benchmark data (~8%) actually falls below this range, which tells you the market is currently skewed toward buyer-favorable structures.
• Conviction Ratio 5%–15%: The buyer is hedging. They want the asset but aren't willing to pay for the risk. This is the zone where most Phase 2 deals land in practice, and it requires careful milestone analysis to determine whether the deal is genuinely valuable.
• Conviction Ratio < 5% (or 0%): This is an option, not a partnership. The buyer has near-zero skin in the game. The Earendil, RemeGen, and Capstan deals all fall here. These structures can work for platform companies with multiple shots on goal, but for single-asset biotechs, they're dangerous.

We recommend using the Conviction Ratio alongside probability-adjusted total value to build a complete picture. Our Deal Calculator now includes Conviction Ratio benchmarking by phase, modality, and therapeutic area.

What the data actually says: The median Conviction Ratio for Phase 2 anti-VEGF immunology deals is approximately 8%. That's in the hedging zone. Founders who want to push that ratio higher need competitive tension, clean data packages, and a clear regulatory path. Buyers who are offered ratios above 30% should pressure-test whether they're overpaying for optionality they could acquire more cheaply.

Why Conventional Wisdom Is Wrong About Milestone-Heavy Deal Structures

The prevailing narrative in biotech BD circles is that milestone-heavy deals are fine because "the total value is what matters." This is wrong, and the 2025 data proves it.

Here's the contrarian thesis: milestone-heavy deal structures systematically destroy value for licensors, and most founders don't realize it until it's too late.

Consider a Phase 2 anti-VEGF immunology deal with $60M upfront and $2.44B in milestones (total value $2.5B, Conviction Ratio 2.4%). That $2.44B in milestones is typically structured as follows:

• Phase 3 initiation: $50M–$100M
• Phase 3 data readout: $100M–$200M
• First regulatory approval (US): $150M–$300M
• Second regulatory approval (EU/Japan): $75M–$150M
• First commercial sales milestone ($500M): $100M–$200M
• Second commercial sales milestone ($1B): $200M–$400M
• Third commercial sales milestone ($2B+): $300M–$600M

Now probability-adjust these. Phase 2 to approval in immunology runs roughly 25%–35% depending on the indication. The probability of hitting $2B+ in annual sales for a new anti-VEGF immunology product is well under 10%. When you run the math, the expected value of $2.44B in milestones is $400M–$700M. Add the $60M upfront, and the probability-weighted deal value is $460M–$760M. That's not a $2.5B deal. It's a sub-$1B deal with a good press release.

The hidden cost goes further. Milestone-heavy structures create perverse incentives for the licensee. If the Phase 3 data is ambiguous — not a clear win, not a clear fail — the licensee has a financial incentive to delay or restructure rather than trigger the next milestone payment. The licensor has no operational control and limited contractual recourse. Meanwhile, the licensor's stock may have re-rated on the headline deal value, creating a gap between market expectations and economic reality that becomes painful if milestones are delayed or missed.

The tactical response: negotiate minimum annual payments or development timeline commitments with financial penalties for delay. Push for milestones that are binary and objectively verifiable — "first patient dosed" rather than "Phase 3 initiation," which can be defined ambiguously. And always, always model the probability-adjusted value before celebrating the headline.

The Negotiation Playbook for Anti-VEGF Immunology Licensing Deal Terms at Phase 2

This section is tactical. Use it as a checklist before your next term sheet review.

1. Calculate the Conviction Ratio First

Before you read a single milestone, divide the upfront by the total deal value. If it's below 8% (the current median for this segment), you're being offered a below-market structure. That doesn't mean walk away — it means you need compensating terms elsewhere (higher royalties, better tier structures, anti-shelving provisions).

2. Benchmark Against the Right Comps

Don't let a buyer cite a zero-upfront deal like RemeGen-Vor Bio as a comparable for your Phase 2 anti-VEGF asset with strong data. The right comps are deals within the $60M–$250M upfront range with similar data maturity. Use our Immunology Deal Benchmarks to pull the specific ranges.

3. Push Back on Low Upfronts by Citing the Nimbus Precedent

If you have differentiated Phase 2 data and a competitive process, the Nimbus-Takeda deal ($4B upfront on $6B total) is your leverage point. You're not asking for $4B. You're asking for a Conviction Ratio that reflects the quality of your data. The 67% ratio Nimbus achieved proves that buyers will front-load economics when the asset justifies it.

4. Scrutinize Commercial Milestones

Commercial milestones above $1B in annual net sales are aspirational for most anti-VEGF immunology products. If more than 30% of your total deal value is tied to commercial milestones above $1B, the deal is less valuable than it appears. Push for lower commercial thresholds or convert some of that value into upfront or regulatory milestones.

5. Negotiate Royalty Tiers, Not Headline Rates

An 18% royalty that kicks in above $2B in cumulative sales is worth less than a 14% flat rate on all net sales for most anti-VEGF products. Before you accept the term sheet, model the net present value of each royalty tier against your probability-weighted commercial forecast. If the blended effective royalty rate across your realistic sales scenarios is below 12%, the headline rate is misleading.

6. Include Anti-Shelving and Diligence Provisions

Phase 2 licensing deals are particularly vulnerable to shelving — a buyer acquires the rights, then deprioritizes development in favor of an internal asset. Ensure your agreement includes minimum development expenditure requirements, specified timelines for Phase 3 initiation, and reversion rights if milestones are not met within defined windows.

7. Watch for Territory Carve-Outs

Global rights command a premium. If a buyer is asking for worldwide exclusive rights, the upfront should reflect that. If they're offering a regional deal (e.g., US and EU only), the upfront will be lower, but you retain Greater China and Japan rights for a potential second deal. This can be strategically advantageous if you have relationships with regional partners.

For Biotech Founders

You care about one question: what is my Phase 2 anti-VEGF immunology asset worth in a licensing deal?

The answer: $60M–$250M upfront, with a median of $120M, depending on data quality, indication, and competitive dynamics. Total deal value ranges from $700M to $2.5B, but probability-adjusted value is typically 30%–50% of the headline.

Here's what founders consistently get wrong:

• Overweighting total deal value. Your board will love the press release. Your bank account will reflect the upfront. Optimize for the upfront and near-term milestones you'll actually receive.
• Underestimating the power of competitive tension. Running a dual-track process (licensing + IPO/follow-on, or licensing to multiple potential partners) is the single most effective way to increase your upfront. Nimbus didn't get $4B upfront by negotiating with one buyer.
• Ignoring the Conviction Ratio. A $2B total deal value with $0 upfront is not a $2B deal. It's a $0 deal with $2B in possibilities. If you need capital to fund operations, the Conviction Ratio tells you whether this deal solves your problem.
• Failing to model scenarios. Use our Deal Calculator to run probability-adjusted models across your specific deal terms. What's the expected value if Phase 3 succeeds? What if it fails? What if it generates ambiguous data and the buyer delays?

One more thing: if you're considering an anti-VEGF immunology asset out-license at Phase 2, do it before you need the money. Desperation is the most expensive negotiating position in biopharma.

For BD Professionals

You care about a different question: can I defend this deal to my deal committee?

Here's how to build the case — or tear one apart.

If you're the buyer:

• Anchor your upfront offer at or below $120M (the median). Justify it with the Phase 2 benchmark data. If the asset has early Phase 2a data, push toward $60M. If it has late Phase 2b data with a registrational path, be prepared to go to $200M+ — but extract concessions on royalty tiers or territory.
• Structure milestones to gate your exposure. Your deal committee will approve a $2B total deal value if 80% of it is contingent on events you control (Phase 3 design, filing strategy, commercial execution). They won't approve a $500M upfront unless the data is extraordinary.
• Use the zero-upfront comps (RemeGen, Earendil, Capstan) as evidence that the market supports option-style structures. But be honest with yourself: those deals were for earlier-stage or platform assets. A differentiated Phase 2 asset with clean data deserves a real upfront.

If you're the seller's BD advisor:

• Never present total deal value as the primary metric to your board or investors. Lead with the upfront, the Conviction Ratio, and the probability-adjusted value. If your board is making decisions based on headline total value, you have an education problem.
• Build a comp table that includes both licensing deals and acquisitions. Blueprint-Sanofi at $9.5B and Nimbus-Takeda at $6B establish the ceiling. Your Phase 2 licensing deal should capture a meaningful fraction of acquisition value — typically 20%–40% — in probability-adjusted terms.
• Red flag: if a buyer offers a Conviction Ratio below 5% with no strategic rationale (e.g., platform deal, option on multiple assets), they're not serious. Either renegotiate the upfront or walk.

For a comprehensive overview of how these deals fit into the broader immunology landscape, see our Therapeutic Area Overview for Immunology.

What Comes Next for Anti-VEGF Immunology Licensing Deal Terms at Phase 2

Here are three predictions for the next 12–18 months:

1. Upfront payments will bifurcate further. The $60M–$250M range will widen. Assets with differentiated mechanisms and strong Phase 2b data will command $200M+ upfronts as buyers with patent cliffs become more aggressive. Assets with early or undifferentiated data will see upfronts compressed toward $40M–$60M as buyers adopt option structures modeled on the RemeGen and Earendil deals.

2. Royalty rates will hold steady but tier structures will get more complex. Expect to see more deals with four or five royalty tiers, biosimilar step-downs, indication-specific rates, and co-promotion adjustments. The headline rate matters less every year. The effective blended rate is the only number worth modeling.

3. The Conviction Ratio will become a standard metric. As more sophisticated biotech boards demand transparency on deal quality, the gap between headline total value and probability-adjusted value will become harder to ignore. We expect leading biotech advisors and investment banks to adopt upfront-ratio or conviction-ratio metrics as standard in deal marketing materials within the next two years.

The bottom line: the anti-VEGF immunology licensing market at Phase 2 is active, competitive, and structurally nuanced. The buyers are sophisticated. The sellers need to be equally so. If you're entering a process, know your numbers, know your comps, and know your walk-away. The data gives you leverage — but only if you use it.

For a personalized analysis of how your asset benchmarks against these data points, request a full deal report from the Ambrosia Ventures team.